Macrophage models of gaucher disease for evaluating disease pathogenesis and candidate drugs

Science Translational Medicine

Volumn 6, Issue 240, 2014, Pages

  Aflaki, Elma ^a   Stubblefield, Barbara K ^a   Maniwang, Emerson ^a   Lopez, Grisel ^a   Moaven, Nima ^a   Goldin, Ehud ^a,d   Marugan, Juan ^b   Patnaik, Samarjit ^b   Dutra, Amalia ^c   Southall, Noel ^b   Zheng, Wei ^b   Tayebi, Nahid ^a   Sidransky, Ellen ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d SENS Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLUCOSYLSPHINGOSINE; IMIGLUCERASE; NCGC 00188758; REACTIVE OXYGEN METABOLITE; SPHINGOLIPID; UNCLASSIFIED DRUG; PSYCHOSINE; SPHINGOSYL BETA-GLUCOSIDE;

ARTICLE; CHEMOTAXIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESEARCH; ENZYME ACTIVITY; FIBROBLAST CULTURE; GAUCHER DISEASE; GAUCHER DISEASE TYPE 1; GENE MUTATION; HUMAN; HUMAN CELL; LIPID STORAGE; LYSOSOME; MACROPHAGE; MONOCYTE; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTOSIS; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CELL CULTURE; CYTOLOGY; INDUCED PLURIPOTENT STEM CELL; METABOLISM; PATHOLOGY;

CELLS, CULTURED; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LYSOSOMES; MACROPHAGES; MONOCYTES; PSYCHOSINE;

EID: 84903179045     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008659     Document Type: Article

References (38)

1. G. A. Grabowski, E. Beutler, The Metabolic and Molecular Bases of Inherited Disease (McGraw-Hill, New York, 2001), pp. 3635-3668.
2. E. Orvisky, J. K. Park, M. E. LaMarca, E. I. Ginns, B. M. Martin, N. Tayebi, E. Sidransky, Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: Correlation with phenotype and genotype. Mol. Genet. Metab. 76, 262-270 (2002).
3. R. E. Lee, The fine structure of the cerebroside occurring in Gaucher's disease. Proc. Natl. Acad. Sci. U.S.A. 61, 484-489 (1968).
4. E. Sidransky, M. A. Nalls, J. O. Aasly, J. Aharon-Peretz, G. Annesi, E. R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, A. Brice, C. M. Chen, L. N. Clark, C. Condroyer, E. V. De Marco, A. Dürr, M. J. Eblan, S. Fahn, M. J. Farrer, H. C. Fung, Z. Gan-Or, T. Gasser, R. Gershoni-Baruch, N. Giladi, A. Griffith, T. Gurevich, C. Januario, P. Kropp, A. E. Lang, G. J. Lee-Chen, S. Lesage, K. Marder, I. F. Mata, A. Mirelman, J. Mitsui, I. Mizuta, G. Nicoletti, C. Oliveira, R. Ottman, A. Orr-Urtreger, L. V. Pereira, A. Quattrone, E. Rogaeva, A. Rolfs, H. Rosenbaum, R. Rozenberg, A. Samii, T. Samaddar, C. Schulte,M. Sharma,A. Singleton, M. Spitz, E. K. Tan, N. Tayebi, T. Toda, A. R. Troiano, S. Tsuji, M. Wittstock, T. G. Wolfsberg, Y. R. Wu, C. P. Zabetian, Y. Zhao, S. G. Ziegler, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661 (2009).
5. S. J. Gardai, K. A. McPhillips, S. C. Frasch, W. J. Janssen, A. Starefeldt, J. E. Murphy-Ullrich, D. L. Bratton, P. A. Oldenborg, M. Michalak, P. M. Henson, Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321-334 (2005).
6. J. V. Ravetch, Fc receptors. Curr. Opin. Immunol. 9, 121-125 (1997).
7. B. M. Babior, NADPH oxidase. Curr. Opin. Immunol. 16, 42-47 (2004).
8. Y. Suzuki, Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev. 35, 515-523 (2013).
9. K. E.Murphy, A. M.Gysbers, S. K. Abbott, N. Tayebi,W. S. Kim, E. Sidransky, A. Cooper, B. Garner, G. M. Halliday, Reduced glucocerebrosidase is associated with increased a-synuclein in sporadic Parkinson's disease. Brain 137, 834-848 (2014).
10. M. E. Gegg, D. Burke, S. J. Heales, J. M. Cooper, J. Hardy, N. W. Wood, A. H. Schapira, Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455-463 (2012).
11. E. Goldin, W. Zheng, O. Motabar, N. Southall, J. H. Choi, J. Marugan, C. P. Austin, E. Sidransky, High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLOS One 7, e29861 (2012).
12. S. Patnaik, W. Zheng, J. H. Choi, O. Motabar, N. Southall, W. Westbroek, W. A. Lea, A. Velayati, E. Goldin, E. Sidransky, W. Leister, J. J. Marugan, Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem. 55, 5734-5748 (2012).
13. L.M. Panicker, D. Miller, T. S. Park, B. Patel, J. L. Azevedo, O. Awad,M. A.Masood, T. D. Veenstra, E. Goldin, B. K. Stubblefield, N. Tayebi, S. K. Polumuri, S. N. Vogel, E. Sidransky, E. T. Zambidis, R. A. Feldman, Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 109, 18054-18059 (2012).
14. K. R. Karlsson, S. Cowley, F. O. Martinez, M. Shaw, S. L. Minger, W. James, Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp. Hematol. 36, 1167-1175 (2008).
15. J. M. Rybicka, D. R. Balce, M. F. Khan, R. M. Krohn, R. M. Yates, NADPH oxidase activity controls phagosomal proteolysis in macrophages through modulation of the lumenal redox environment of phagosomes. Proc. Natl. Acad. Sci. U.S.A. 107, 10496-10501 (2010).
16. H. J. Møller, M. de Fost, H. Aerts, C. Hollak, S. K. Moestrup, Plasma level of the macrophagederived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur. J. Haematol. 72, 135 -139 (2004).
17. T. Farfel-Becker, E. B. Vitner, A. H. Futerman, Animal models for Gaucher disease research. Dis. Models Mech. 4, 746-752 (2011).
18. P. K. Mistry, J. Liu, M. Yang, T. Nottoli, J. McGrath, D. Jain, K. Zhang, J. Keutzer, W. L. Chuang, W. Z. Mehal, H. Zhao, A. Lin, S. Mane, X. Liu, Y. Z. Peng, J. H. Li, M. Agrawal, L. L. Zhu, H. C. Blair, L. J. Robinson, J. Iqbal, L. Sun, M. Zaidi, Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc. Natl. Acad. Sci. U.S.A. 107, 19473-19478 (2010).
19. N. Dekker, L. van Dussen, C. E. Hollak, H. Overkleeft, S. Scheij, K. Ghauharali, M. J. van Breemen, M. J. Ferraz, J. E. Groener, M. Maas, F. A. Wijburg, D. Speijer, A. Tylki-Szymanska, P. K. Mistry, R. G. Boot, J. M. Aerts, Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood 118, e118-e127 (2011).
20. S. S. Raghavan, R. A. Mumford, J. N. Kanfer, Deficiency of glucosylsphingosine: β-Glucosidase in Gaucher disease. Biochem. Biophys. Res. Commun. 54, 256-263 (1973).
21. N. J. Weinreb, J. Charrow, H. C. Andersson, P. Kaplan, E. H. Kolodny, P. Mistry, G. Pastores, B. E. Rosenbloom, C. R. Scott, R. S. Wappner, A. Zimran, Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am. J. Med. 113, 112-119 (2002).
22. G. Altarescu, S. Hill, E. Wiggs, N. Jeffries, C. Kreps, C. C. Parker, R. O. Brady, N. W. Barton, R. Schiffmann, The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr. 138, 539-547 (2001).
23. S. M. Van Patten, H. Hughes, M. R. Huff, P. A. Piepenhagen, J. Waire, H. Qiu, C. Ganesa, D. Reczek, P. V. Ward, J. P. Kutzko, T. Edmunds, Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 17, 467-478 (2007).
24. R. Khanna, E. R. Benjamin, L. Pellegrino, A. Schilling, B. A. Rigat, R. Soska, H. Nafar, B. E. Ranes, J. Feng, Y. Lun, A. C. Powe, D. J. Palling, B. A. Wustman, R. Schiffmann, D. J. Mahuran, D. J. Lockhart, K. J. Valenzano, The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of b-glucosidase. FEBS J. 277, 1618-1638 (2010).
25. M. A. Cabrera-Salazar, E. Novelli, J. A. Barranger, Gene therapy for the lysosomal storage disorders. Curr. Opin. Mol. Ther. 4, 349-358 (2002).
26. A. R. Sawkar, M. Schmitz, K. P. Zimmer, D. Reczek, T. Edmunds, W. E. Balch, J. W. Kelly, Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem. Biol. 1, 235-251 (2006).
27. W. Zheng, J. Padia, D. J. Urban, A. Jadhav, O. Goker-Alpan, A. Simeonov, E. Goldin, D. Auld, M. E. LaMarca, J. Inglese, C. P. Austin, E. Sidransky, Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 104, 13192-13197 (2007).
28. J. J. Marugan, W. Huang, O. Motabar, W. Zheng, J. Xiao, S. Patnaik, N. Southall, W. Westbroek, W. A. Lea, A. Simeonov, E. Goldin, M. A. Debernardi, E. Sidransky, Non-iminosugar glucocerebrosidase small molecule chaperones. Medchemcomm 3, 56-60 (2012).
29. phox component of NADPH oxidase is not the voltage-gated proton channel in phagocytes, but it helps. J. Biol. Chem. 276, 36063-36066 (2001).
30. Y. Groemping, K. Rittinger, Activation and assembly of the NADPH oxidase: A structural perspective. Biochem. J. 386, 401-416 (2005).
31. phox PX domains of NADPH oxidase target cell membranes via direct and indirect recruitment by phosphoinositides. J. Biol. Chem. 277, 4512-4518 (2002).
32. J. R. Mazzulli, Y. H. Xu, Y. Sun, A. L. Knight, P. J. McLean, G. A. Caldwell, E. Sidransky, G. A. Grabowski, D. Krainc, Gaucher disease glucocerebrosidase and a-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011).
33. D. L. Stone, N. Tayebi, E. Orvisky, B. Stubblefield, V. Madike, E. Sidransky, Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum. Mutat. 15, 181-188 (2000).
34. C. von der Heul, M. J. Kroos, C. M. de Jeu-Jaspars, H. G. von Eijk, The uptake of iron by reticulocytes. The influence of purification of the ghosts on iron-containing components in the ghost suspension. Biochim. Biophys. Acta 601, 572-583 (1980).
35. G. Tiscornia, E. Lorenzo Vivas, L. Matalonga, I. Berniakovich, M. Barragán Monasterio, C. Eguizábal, L. Gort, F. González, C. Ortiz Mellet, J. M. García Fernández, A. Ribes, A. Veiga, J. C. Izpisua Belmonte, Neuronopathic Gaucher's disease: Induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum. Mol. Genet. 22, 633-645 (2013).
36. E. Schröck, S. du Manoir, T. Veldman, B. Schoell, J. Wienberg, M. A. Ferguson-Smith, Y. Ning, D. H. Ledbetter, I. Bar-Am, D. Soenksen, Y. Garini, T. Ried, Multicolor spectral karyotyping of human chromosomes. Science 273, 494-497 (1996).
37. -ΔΔCT method. Methods 25, 402-408 (2001).
38. E. Aflaki, N. A. Balenga, P. Luschnig-Schratl, H. Wolinski, S. Povoden, P. G. Chandak, J. G. Bogner-Strauss, S. Eder, V. Konya, S. D. Kohlwein, A. Heinemann, D. Kratky, Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis. Cell. Mol. Life Sci. 68, 3933-3947 (2011).